Latest NewsNov 4, 2024HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in-Class BTLA Agonist Antibody for the Treatment of Inflammatory and Immunology Diseases All Filter By: Year2024202320222021202020192018201720162015Apr 16, 2024HiFiBiO Therapeutics Receives Grant to Research Long COVID and ME/CFS in Collaboration with UMass Chan Medical SchoolApr 7, 2024HiFiBiO Therapeutics Presents Two Posters at the 2024 American Association for Cancer Research Annual MeetingMar 21, 2024HiFiBiO Therapeutics to Present at 2024 American Association for Cancer Research Annual MeetingNasdaq Live from MarketSite | Interview | Jan 7, 2024CEO Liang Schweizer Sits with Nasdaq to Share HiFiBiO Therapeutics’ Mission to Unlock the Curative Powers of the Immune SystemDec 11, 2023HiFiBiO Therapeutics Collaborates with Institut Gustave Roussy and France 2030 Initiative to Pioneer Personalized Immunotherapies< 1 2 3 4 … 17 >
